// App-Quantinova.ai

AEP130 : Phase II study of the impact of AZD4017, a selective 11β-HSD1 inhibitor, on osteocalcin in post-menopausal osteopenia

Researchers

Presenter

  • Afroze Abbas

Principal Investigators

  • Richard Eastell

  • Rachel K Crowley

  • Gemma Ainsworth

  • Sarah Brown

  • Louise M Flanagan

  • Rebecca J Fairclough

  • Paul M Stewart

Medical Centers

  • University of Sheffield School of Medicine, Sheffield, United Kingdom

  • Mellanby Centre for Bone Research, Academic Unit of Bone Metabolism, Sheffield, United Kingdom

  • St Vincent's University Hospital, Dublin, Ireland

  • University of Leeds, Clinical Trials Research Unit, United Kingdom

  • Emerging Innovations Unit, Discovery Sciences, R&D, Astrazeneca, Cambridge, United Kingdom

Locations

  • United Kingdom

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoporosis

  • Osteopenia

Biomarkers

  • Cortisol

  • Body mass index

Drug/Treatment

  • Glucocorticoid

  • AZD-4017

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved